On Monday, SolarCity Corp (NASDAQ:SCTY)’s shares declined -2.41% to $54.74, as SolarCity(R), declared a partnership with Nest Labs, creator of the Nest Learning Thermostat(TM), to make saving money on energy even easier for customers.
Starting, the first 10,000 new customers in California who sign up with SolarCity will receive a Nest Thermostat installed at no additional cost. To qualify, customers must have a compatible air conditioning system and agree to connect their Nest Thermostat to SolarCity as part of the Works with Nest program.
SolarCity Corporation designs, manufactures, installs, maintains, monitors, leases, and sells solar energy systems to residential, commercial, government, and other customers in the United States. It offers solar energy systems; solar lease and power purchase contract finance products; mounting hardware for photovoltaic panels; and related software, in addition to develops a proprietary battery administration system, which is designed to enable remote, bidirectional control of distributed energy storage that can provide benefits to customers, utilities, and grid operators.
Mylan NV (NASDAQ:MYL)’s shares dropped -2.39% to $68.56, during the last trading session on Monday, as Mylan N.V. declared that it has offered Perrigo Corporation plc (NYSE: PRGO; TASE) with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its projected attainment of Perrigo, as required by the HSR Act. Mylan projected to attain Perrigo for $205 per share in a cash-and-stock transaction on April 6, 2015.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The corporation provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
At the end of Monday’s trade, Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s shares dipped -2.38% to $11.90, as Amicus Therapeutics, will support several activities surrounding Fabry Disease Awareness Month and International Pompe Day. The Fabry community has designated the month of April to honor and recognize those who are affected by the disease and to promote greater awareness of the disease. The aim of the Second International Pompe Day on April 15 is to foster international awareness of Pompe disease.
Amicus Therapeutics, Inc., a biopharmaceutical corporation, focuses on the discovery, development, and commercialization of medicines for various rare and orphan diseases. Its product candidate is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Check Point Software Technologies Ltd. (NASDAQ:CHKP), ended its Monday’s trading session with -2.37% loss, and closed at $82.91, as Check Point® Software Technologies, declared that it will release its first quarter financial results for the quarter ending March 31, 2015, on Monday, April 20, 2015, before the U.S. financial markets open.
Administration will host a conference call with the investment community at 8:30 AM ET/5:30 AM PT on April 20. A live webcast of the call will be hosted on the corporation’s website at http://www.checkpoint.com/ir.
Check Point Software Technologies Ltd. develops, markets, and supports a range of software, combined hardware, and software products and services for information technology (IT) security worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
